#Aurobindopharma

Aurobindo CMP 868The company is developing:14 Biosimilars (5 of these expected to launch by FY25 with a US$20 market size)8 inhalers (US market size is >$10 Bn)Pneumcoccal Conjugate Vaccine (US$6.2
Read more
By continuing to use the site, you are consenting to the use of cookies as explained in our Cookie Policy to improve your experience.